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COLLAGEN-induced arthritis (CIA) is an immunologically
relevant animal model of human rheumatoid arthritis.
Studies comparing the disease incidence in genetically
susceptible male and female DBA/1LacJ mice demon-
strated that under low density/low stress housing condi-
tions, female mice had earlier onset (day 35) and higher
disease incidence (25%) than the male mice (17% at day
49) when immunized with bovine type II collagen. A
single subcutaneous or intraperitoneal injection of bacter-
ial lipopolysaccharide (LPS) 17-24 days after collagen
immunization greatly potentiated this standard CIA model
in a dose related manner. 20-40 jig of LPS accelerated the
onset of disease from day 35 to day 21 and exacerbated the
clinical severity score from 0.27 to 2.00 at day 42. A similar
administration of 6 jig of recombinant interleukin-l pro-
duced a comparable potentiated CIA model. The acute
phase protein, serum amyloid P (SAP), was elevated in the
serum at day 26 to 440 jig ml-1 for the LPS potentiated CIA
mice compared to 65 jig m1-1 in the non-potentiated im-
munized CIA mice. There was a significant correlation
(r 0.78) between SAP levels and disease expression in
the LPS treated CIA mice. The rapidity and uniformity of
disease expression in this LPS potentiated CIA model will
allow more and different drugs to be evaluated with a
smaller number of animals.
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Introduction
Collagen-induced arthritis (CIA) is a polyarthritis
induced by immunization with native type II
collagen in genetically susceptible strains of
animals. This model of arthritis has been established
in both the rat1’2 and mouse. 3’4 Its clinical and
histopathological manifestations closely resemble
those of human rheumatoid arthritis (RA).
However, as a pharmacological model for drug
discovery, CIA has certain disadvantages. The
onset, incidence, and severity of arthritis is highly
variable within and among experiments. It has also
been reported that male mice are usually more
susceptible to CIA than females and that the
immune response to a species specific type II
collagen (e.g. chick vs bovine) varies in different
mouse strains.
6 These parameters were investigated
using the DBA/1LacJ mouse ClA model under
controlled housing conditions.
It has recently been shown that exogenously
administered human recombinant interleukin-1
(IL-1) can potentiate the development of CIA. 7’8
Since exogenous lipopolysaccharide (LPS) is known
to stimulate endogenous IL-1 release, we tested the
effects of LPS on CIA expression. We investigated
the dose response effects ofLPS on onset, incidence,
and severity and also examined the acute phase
protein (APP) response in this disease model. These
results were compared to the IL-1 potentiated CIA.
Materials and Methods
Materials: Chicken type II collagen from lathyritic
chicks was obtained from Genzyme Corporation,
Boston, MA. Bovine type II collagen from calf
articular cartilage was obtained from Elastin
Products Co., Pacific, MO. Bacterial lipopoly-
saccharide from Escherichia coli strain D127 :B8 and
complete Freund’s adjuvant (CFA), strain H37Ra,
were obtained from Difco Laboratories, Detroit,
MI. Purina Chow, Formula 5015, was obtained
from Purina Mills Inc., St. Louis, MO. Re-
combinant human interleukin-1 beta (rIL-lfl)
was obtained from Biogen Corp., Cambridge, MA.
DBA/1 LacJ mice, 5--6 weeks old, were obtained
from the Jackson Laboratory, Bar Harbor, ME.
Methods: DBA/1 LacJ mice, 5-6 weeks old, were
housed three to a shoebox-type cage equipped with
a microisolator filter cap and corncob bedding.
Food and water (steam sterilized tap water) were
provided ad libitum. Cages were changed weekly.
After initial caging, care was taken not to introduce
new litter mates or otherwise ’mix’ the mice. The
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animals were kept in a barrier facility used
exclusively for these experiments.
At age 8--12 weeks mice were immunized
intradermally at the base of the tail with 0.1 ml of
an emulsion of type II collagen prepared in the
following manner. Type II collagens were solubi-
lized in 0.01 N acetic acid and emulsified with CFA
(1:1 v/v). In experiments where a secondary
immunization (booster) was administered, the
collagen emulsion was injected at day 21 at the same
concentration used in the primary immunization.
LPS or IL-1 was injected either subcutaneously
(s.c.) or intraperitoneally (i.p.) 17-24 days after
immunization. Treatment groups consisted of 9-15
mice.
Mice were assessed 3 days after challenge and
weekly thereafter for incidence, frequency and
severity score defined as follows: incidence is the
number of mice having at least one affected paw
(inflammation or joint deformity) divided by the
total number of mice per group; frequency is the
number of affected paws divided by the total
number of paws per group; and the severity score
is the sum of the individual clinical scores divided
by the total number of mice per group.
The clinical score was determined as follows:
Mild synovitis, no cartilage
degeneration or bone changes
Moderate synovitis, mild
cartilage and bone changes
Marked synovial inflammation,
fibroblast proliferation,
cartilage damage and periosteal
bone proliferation
Severe synovitis, cartilage
damage, periosteal bone
proliferation and medullary
remodelling
Statistical differences between control and
treated groups were determined by the least
significant difference test with all possible pairwise
comparisons with p _< 0.05 considered significant.
Mice were bled on day 26 or 28 by retro-orbital
plexus method. The sera were collected and frozen
until assayed for SAP. SAP was quantitated by
SDS-PAGE and immunoblotting technique accord-
ing to the method of Griswold et al. The
relationship between clinical score and SAP was
analysed by linear regression analysis to determine
the correlation coefficient.
Clinical Score
0.5
1.0
2.0
3.0
Description
One or more swollen digits
Entire paw swollen
Deformity observed after
inflammation subsides
Ankylosis: total loss of
joint function in the paw
At the conclusion of the studies the entire
limb was removed above the knee or elbow, fixed
in 10% buffered formalin and sent for histological
processing and analysis of joint pathology.
Evaluations were performed by Research Pathology
Services, Inc., New Britain, PA, in a single blind
fashion and the degree of arthritis determined in
the forepaw (carpal), knee (stifle) and hindpaw
(tarsal/metatarsal). Histopathological incidence is
defined as the number of joints with at least one
lesion divided by the total number of assessed joints
per group. Histopathological severity is the sum of
the individual joint histopathological scores divided
by the number of mice per group. A histopathologi-
cal score similar to that used by Hom et al. was
assigned to each joint based on the following
criteria:
Histopathological
Score
0
1
Description
No alterations
Minimal synovitis, primarily
infiltration of mononuclear
cells into synovial membrane
Results
Comparison of arthritic responses in male and female
1)BA/lLacJ mice using a single injection of chick or bovine
type H collagen: The susceptibility of male and
female mice to arthritis using increasing concentra-
tions of collagen to induce arthritis is reported in
Table 1. The results showed that in mice housed
under well controlled, low stress conditions,
susceptibility to arthritis was greater in females than
in males. Only 25% of the male mice injected with
100/g of chick or bovine collagen became arthritic
at day 49-60 (Table 1). In contrast, the female mice
given chick collagen showed signs of arthritis as
early as day 35 and when the mice received 200 #g
of bovine type I1 collagen, arthritis was observed
at day 21 (Table 1). Under all conditions, the
highest incidence of arthritis achieved was 50%.
Effect of a collagen booster immunization on arthritis induction
in male andfemale mice: Mice that were immunized on
day 0 and also received a booster injection of
collagen on day 21, showed a greatly enhanced level
of arthritic incidence in both male and female mice
along with a much earlier onset of disease compared
to non-boosted mice (Table 2). When the mice were
immunized with either chick or bovine collagen,
the female mice had an earlier onset of disease and
higher levels of incidence and freqency of arthritis
at every time point evaluated than the male mice
(Table 2). As an example, female mice which
received a 50 #g booster of chick collagen reached
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Table 1. Effect on disease incidence after a single collagen immunization with chick or bovine
type II collagen in male and female mice
Days of observation
Dose of
Sex collagen (#g) 21 28 35 42 49 53(F) or 60(M)
Chick type II
Males
Females
Bovine type II
Males
Females
2.5 0 0 0 0 0 0
25 0 0 0 0 0 0
50 0 0 0 0 0 0
100 0 0 0 0 17 25(1.3)
b
12.5 0 0 0 0 0 0
25 0 0 8(1 33 33(1.5)
50 0 0 8(1) 17 42(1.2)
100 0 0 25(1.3) 25 50(1.8)
50 0 0 0 0 8 8(1)
100 0 0 0 0 25 25(1.6)
200 0 0 0 0 0 8(1
50 0 0 0 0 17(1)
100 0 0 0 0 33(1.25)
200 8 8 17(1) 33 25(2)
n 10-12 mice/group.
Incidence number of mice having at least one affected paw divided by the number of mice
per group and expressed as a percentage.
Mean number of affected paws per affected mouse.
a 100% level of incidence by day 42 while the
highest incidence achieved in the males under the
same conditions was 42% at day 56.
Dose related effects of LPS on CIA in mice: Female
DBA/1LacJ mice were immunized with 25/g of
bovine type II collagen for studies involving LPS.
Mice which received 1, 10, or 100/g of LPS on
day 17 produced a dose related increase in disease
incidence of 0%, 50% and 83%, respectively, on day
21 (Figure 1). Mice injected on day 21 with PBS,
1/g LPS, or 10/g LPS attained 67% incidence
level on days 70, 56, and 42, respectively. In another
study, 10-100 #g of LPS per mouse was injected
s.c. on day 21 to collagen immunized mice. The
results shown in Figure 2 indicate a dose related
Table 2. Effect on disease incidence after a collagen immunization plus boost (day 21) with
chick or bovine type II collagen in male and female mice
Days of observation
Dose of
Sex collagen (#g) 28 35 42 49 56 63
Chick type II
Males
Females
Bovine type II
Males
Females
12.5 0 0 0 8 17 17(1)
b
25 0 0 8 17 33 33(1.25)
50 8 18 33 33 42 36(1.75)
100 0 17 25 17 33 33(1.5)
12.5 17 50(2) 58 75 75 92(2.2)
25 17 33(1.5) 50 58 58 67(1.6)
50 42 70(1.4) 100 100 100 100(2.9)
100 33 50(2) 50 75 83 83(2.3)
50 0 0 0 0 0 0
100 17 8 25 17 8 8(2)
200 17 33 50 67 67 50(1.7)
50 67 85(2.2) 85 85 77 85(2.8)
100 33 58(1.3) 73 82 91 91 (2.1)
200 75 75(2.6) 75 75 83 83(2.7)
n 10-12 mice/group
Incidence the number of mice having at least one affected paw divided by the number of
mice per group and expressed as a percentage.
Mean number of affected paws per affected mouse.
Collagen injected i.d. for the boost was the same as for the primary immunization.
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FIG 1. Time course of onset and incidence of CIA in female mice after 1,
10 or 100g of LPS per mouse. LPS was administered s.c. on day 17
post collagen immunization. (n 2/group).
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FIG. 2. Dose related effects of LPS on incidence and frequency at day 24
on CIA in female mice. LPS was administered s.c. on day 7 post collagen
immunization. (n 10/group).
increase in incidence and frequency on day 24.
Similar results were observed when LPS was
administered on day 24 (data not shown). It should
be noted that CFA emulsion alone (day 0), LPS
alone (day 21), or emulsion (day 0) and LPS (day
21) caused no incidence of arthritis to occur in these
mice.
Comparison of LPS potentiated CIA to bovine collagen
immunized and boosted mice: The combined results of
studies in which the LPS potentiated CIA was
compared to collagen immunized and collagen plus
boost immunized CIA showed that female mice
sensitized with 50/g of collagen alone had 0%
incidence and 0% frequency on day 28 while those
animals immunized with collagen and also boosted
with 50/4g of collagen on day 21 had 67% incidence
and 21% frequency on day 28. Those mice which
were immunized with 25/4g of collagen and given
40/g of LPS on day 21 had 90% incidence and 70%
frequency on day 28.
Comparison of LPS and IL-1 potentiated CIA: An
experiment was conducted to compare LPS and
IL-1 potentiated CIA. Table 3 indicates that 40 #g
of LPS injected on day 21 gave an almost equivalent
arthritic response to 3 #g of IL-1 injected on day
21 and 22. Using either potentiating agent, the onset
of disease occurred on day 25, 3 days post challenge.
Clinical incidence was 80% for both LPS and IL-1
treated groups while control (PBS injected)
collagen immunized mice showed no incidence on
day 25. From day 25 to 42 clinical incidence and
severity scores remained elevated and constant for
the LPS or IL-1 treated groups while the vehicle
(PBS) injected collagen immunized group had
Table 3. Effect of LPS or IL-1 treatment on clinical parameters of CIA during disease
development in female mice
Days of observation
Sensitized Clinical
group parameter 25 28 35 42
25/zg Bov collagen (day 0)
+PBS (day 21)
25 #g Bov collagen (day 0)
+40 #g LPS (day 21
25/g Bov collagen (day 0)
+3 #g IL-1 (day 21 & 22)
Incidence (o)a 0 20 27 40
Frequency (%)b 0 5 7 10
Severity score 0 0.10 0.17 0.27
Incidence (%) 80 87 73 80
Frequency (%) 48 48 45 52
Severity score 1.86 1.80 1.60 2.00
Incidence (%) 80 80 80 80
Frequency (%) 65 67 65 65
Severity score 2.43 2.43 2.50 2.50
n 15 mice/group.
Incidence the number of mice having at least one affected paw divided by the number
of mice per group and expressed as a percentage.
b Frequency the number of affected paws divided by the total number of paws per group
and expressed as a percentage.
Severity score the sum of the individual clinical scores (see Methods) divided by the
total number of mice per group.
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Table 4. Effect of LPS or L-1 treatment on histopathological parameters of
CIA at day 42 in female mice
Sensitized
group
H istopathological parameter
Incidence (%)a Mean Severity score
25 #g Bovine collagen (day 0)
+ PBS (day 21
25 #g Bovine collagen (day 0)
+40 #g LPS (day 21)
25 #g Bovine collagen (day 0)
+3 #g IL-1 (day 21 & 22)
44 2.07
64 4.60*
62 4.93*
n 15 mice/group.
p _< 0.05, compared to immunized mice without LPS or IL-1 treatment.
Incidence the number of joints with at least one lesion (e.g.
synovitis, cell infiltration, cartilage degeneration, bone changes) divided by
the total number of assessed joints per group and expressed as a percentage.
b Severity score the sum of the individual joint histopathological scores (see
Methods) divided by the number of mice per group.
increasing but low clinical incidence and severity
scores during the same period (Table 3).
On day 42 the limbs of the mice from the above
experiment were removed and processed for
histopathological evaluation. Although the degree
of synovitis, cellular infiltration, cartilage de-
gradation, and aberrant bone proliferation varies
within as well as among treatment groups, the LPS
and IL-1 potentiated groups produced similar
histopathological severity scores (4.6 and 4.9,
respectively) at day 42 while the control immunized
group exhibited a severity score (2.1) less than 50%
of the potentiated CIA treated groups (Table 4).
Comparison of SAP levels in mice with LPS or IL-1
potentiated CIA. The acute phase protein, serum
amyloid P (SAP), was measured on the 26th day
after collagen immunization (Table 5), 5 days after
the LPS or IL-1 injection in the female DBA/1LacJ
mice. The SAP levels from the LPS or IL-1
potentiated CIA mice were approximately 10-14
times higher than the naive or emulsion injected
animals and 5-7 times higher than the collagen
immunized non-arthritic mice. The LPS potentiated
immunized mice had SAP levels about twice as high
as their control, nonimmunized but LPS injected
mice (441 #g ml- and 194 #g ml- 1, respectively).
In Fig. 3A and 3B, SAP levels and clinical scores on
day 28 from LPS potentiated or IL-1 potentiated
CIA mice showed significant correlations of
r 0.78 and r 0.85, respectively.
Discussion
In these experiments, we have shown that under
low density/low stress housing conditions, genetic-
ally susceptible DBA/1LacJ female mice exhibit
earlier onset of disease and higher disease incidence
when using either chick or bovine type II collagen
immunization than male mice in the traditional CIA
model. The higher female than male arthritic
response is contrary to what has been reported.
5
The lower CIA response in male mice housed under
Table 5. Effect of LPS or L-1 treatment on SAP levels in
collagen immunized and non-immunized female mice at day 26
Sensitized Clinical SAP level
group Severity score (/g ml-1 serum)
PBS, day 21 0.00 31 4- 3
Emulsion, day 0’ & PBS, day 21 0.00 36 4- 3
LPS only (40/g), day 21 0.00 194 -t- 38
Collagen (25/g), day 0" & PBS 0.00 65 4- 8
day 21
Collagen (25/g), day 0’ & LPS 3.67 441 4- 73*
(40/g), day 21
Collagen (25 #g), day 0" & IL-1 3.00 352 -t- 133"
(2/g), day 21, 22, 23
n- 15 mice/group.
p < 0.05 compared to control mice (emulsion + PBS).
Clinical Severity score- sum of the individual scores divided by the
number of mice per group (see Methods for further detail).
Mean + SEM.
Mediators of Inflammation Vol 1992 277R. G. Caccese, J. L. Zimmerman and R. P. Carlson
7000
6000
5000
4000
3000
2000
1000
7000
6000
5000
4000
3000
2000
1000
LPS (A)
X x
r-0.78
0 2 3 4
Clinical Score
IL-113 (B)
x
x
x
r=0.85
0 2 3 4
Clinical Score
FIG. 3. Positive correlation of clinical scores compared to SAP levels on
day 28, 7 days after CIA mice were injected i.p. with LPS (A) or IL-1 fl (B).
Clinical score is defined in Methods.
SAP levels are expressed as CPM with serum diluted "50 for assay
(see Methods for details).
controlled low density conditions may be due to
the lack of the male fighting syndrome, which
reduces stress in these animals to a minimum. It is
also possible that the usual male fighting could have
led to subclinical infections and their associated
inflammatory mediators which could exacerbate
their CIA. Our results with the male CIA mice
support using female mice in the CIA as a model
of human RA, since it is known that females have
a higher incidence of RA than males.
1
Other investigators have shown that rlL-1/ can
increase the incidence and potentiate CIA in mice. 7,s
This cytokine is known to stimulate the prolifera-
tion of T cells, induce the release of lymphokines,
and activate neutrophils, synoviocytes, chondro-
cytes, osteoblasts and osteoclasts to release
inflammatory mediators, such as eicosanoids and
collagenases.
1 These combined factors may play a
role in the CIA arthritic disease model. We have
demonstrated that LPS, possibly by inducing
endogenous IL-1 release, can also potentiate CIA
in a dose dependent manner. LPS accelerates the
onset and increases the severity of CIA such that
marked inflammation is observed just 72 h after
LPS or IL-1 administration in the collagen
immunized mice. The disease progression in
non-LPS treated mice occurred slowly with variable
onset and gradual increase of incidence from day
28 to day 60-70. The histopathological severity
score for LPS treated mice at day 42 was 200%
greater than the severity score of the non-
potentiated CIA mouse model. These histopatholo-
gical results indicate that the LPS stimulated
arthritic disease at day 42 resembles an advanced
stage of disease seen much later in the normal CIA
model. This is similar to what has been
reported when IL-1 is used as the potentiating
agent.
2 Therefore, it appears that the collagen
immunized mice (i.e. animals with serum anti-type
II collagen antibodies) are ’primed’ to develop
arthritis, and that IL-1 or LPS can be the triggering
mechanism for a rapid induction of arthritis
development.
The APP, C-reactive protein (CRP), is measured
in humans with chronic arthritic disease.
3 We
investigated the APP response in this disease model
using a major murine acute phase reactant, serum
amyloid P, which is structurally related to CRP and
has 70% amino acid homology.
4 Since it is known
that LPS and IL-1 can elevate APP in vitro and in
vivo,
5-18 our results are similar to those reported by
others9’2 using the non-LPS potentiated CIA
model. There was a significant correlation between
clinical severity score and SAP concentration. The
correlation for the IL-1 injected animals was similar
to the LPS treated mice. This potentiated CIA
model showed that the acute phase response is
associated with severity of disease and may be used
as an index of arthritis. With the appearance of
arthritis (paw inflammation) the SAP levels were
increased seven-fold compared to the immunized
non-potentiated mice who had no inflammation.
This difference in elevated SAP levels is probably
a result of cellular influx and cytokine release. SAP
level measurement, as a representative of acute
phase response, may be an indicator of different
mechanisms of action for different classes of drugs
tested in this model.
19
Additional experiments are planned to further
characterize this potentiated CIA model. Areas to
be investigated include" (1) does LPS administra-
tion have an effect on type II collagen antibody
levels; (2) does passive transfer of arthritis last
longer after LPS treatment; (3) does LPS alter the
function of T cells from blood, lymph nodes and
spleens of type II collagen sensitized mice; (4) do
SAP levels correlate with the progression and
severity of disease at later time periods; and (5) does
LPS affect the late stage (day 70-90) parameters
such as ankylosis and bone changes in CIA mice.
The LPS potentiated CIA mouse model has many
advantages for use in pharmacological studies. It
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reduces the latent period required for the
development of arthritis, while producing early
high levels of clinical inflammation and histopatho-
logical incidence of arthritis in a synchronized
disease state. In addition, this model will allow
more drugs to be tested with a smaller number of
animals and to evaluate different classes of drugs
(e.g. anti-inflammatory, immunomodulatory, im-
munosuppressive, and remission inducing drugs) in
both prophylactic and therapeutic regimens. 12’21’22
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